Role of extracellular matrix in vascular remodeling of hypertension

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 2, 2010, Pages 187-194

  Briones, Ana M ^a   Arribas, Silvia M ^a   Salaices, Mercedes ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Collagen; Elastin; Extracellular matrix; Hypertension; Vascular remodeling

Indexed keywords

COLLAGEN; ELASTIN; GLYCOPROTEIN; PROTEOGLYCAN; SCLEROPROTEIN;

ARTERIAL STIFFNESS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CROSS LINKING; EXTRACELLULAR MATRIX; HYPERTENSION; PRIORITY JOURNAL; REVIEW; VASCULAR FIBROSIS; VASCULAR RESISTANCE;

ANIMALS; BLOOD VESSELS; COLLAGEN; ELASTIN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; HYPERTENSION;

EID: 76749162816     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328335eec9     Document Type: Review

References (113)

1. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241.
2. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005; 45:1050-1055.
3. Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 2007; 9:139-144.
4. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108:2230-2235.
5. De Ciuceis C, Porteri E, Rizzoni D, et al. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens 2007; 20:846-852.
6. Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007; 25:1021-1026.
7. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287:H435-H446.
8. VanBavel E, Bakker EN, Pistea A, et al. Mechanics of microvascular remodeling. Clin Hemorheol Microcirc 2006; 34:35-41.
9. Arribas SM, Hinek A, González MC. Elastic fibres and vascular structure in hypertension. Pharmacol Ther 2006; 111:771-791.
10. Sonoyama K, Greenstein A, Price A, et al. Vascular remodeling: implications for small artery function and target organ damage. Ther Adv Cardiovasc Dis 2007; 1:129-137.
11. Feihl F, Liaudet L, Levy BI, Waeber B. Hypertension and microvascular remodelling. Cardiovasc Res 2008; 78:274-285.
12. Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput 2008; 46:461-467.
13. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009; 27:1107-1114.
14. Martinez-Lemus LA, Hill MA, MeiningerGA. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 2009; 24:45-57.
15. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36:312-318.
16. Lacolley P, Challande P, Osborne-Pellegrin M, Regnault V. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res 2009; 81:637-648.
17. Wight TN. Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci 2008; 13:4933-4937.
18. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial me-chanics. Physiol Rev 2009; 89:957-989.
19. Eble JA, Niland S. The extracellular matrix of blood vessels. Curr Pharm Des 2009; 15:1385-1400.
20. Jacob MP, Badier-Commander C, Fontaine V, et al. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001; 49:326-332.
21. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999; 33:569-574.
22. Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91:2638-2642.
23. Gomez-Garre D, Mart́in-Ventura JL, Granados R, et al. Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. Kidney Int 2006; 69:1237-1244.
24. Virdis A, Neves MF, Amiri F, et al. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22:535-542.
25. Briones AM, Xavier FE, Arribas SM, et al. Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 291:H193-H201.
26. Ruperez M, Rodrigues-D́iez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ ROCK and MAPK pathways. Hypertension 2007; 50:377-383.
27. Briones AM, Rodŕiguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009; 54:142-149.
28. Bakker EN, Buus CL, Spaan JA, et al. Small artery remodeling depends on tissue-type transglutaminase. Circ Res 2005; 96:119-126.
29. Bakker EN, Pistea A, VanBavel E. Transglutaminases in vascular biology: relevance for vascular remodeling and atherosclerosis. J Vasc Res 2008; 45:271-278.
30. Rodŕiguez C, Mart́inez-Gonzalez J, Raposo B, et al. Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc Res 2008; 79:7-13.
31. Ooshima A, MidorikawaO. Increased lysyl oxidase activity in blood vessels of hypertensive rats and effect of beta-aminopropionitrile on arteriosclerosis. Jpn Circ J 1977; 41:1337-1340.
32. Lopez B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53:236-242.
33. Keeley FW, Johnson DJ. The effect of developing hypertension on the synthesis and accumulation of elastin in the aorta of the rat. Biochem Cell Biol 1986; 64:38-43.
34. Keeley FW, Alatawi A. Response of aortic elastin synthesis and accumulation to developing hypertension and the inhibitory effect of colchicine on this response. Lab Invest 1991; 64:499-507.
35. Li DY, Brooke B, Davis EC, et al. Elastin is an essential determinant of arterial morphogenesis. Nature 1998; 393:276-280.
36. Faury G, Pezet M, Knutsen RH, et al. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest 2003; 112:1419-1428.
37. Wagenseil JE, Ciliberto CH, Knutsen RH, et al. Reduced vessel elasticity alters cardiovascular structure and function in newborn mice. Circ Res 2009; 104:1217-1224.
38. Martyn CN, Greenwald SE. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet 1997; 350:953-955.
39. Martyn CN, Greenwald SE. A hypothesis about a mechanism for the programming of blood pressure and vascular disease in early life. Clin Exp Pharmacol Physiol 2001; 28:948-951.
40. Hodis S, Zamir M. Mechanical events within the arterial wall: the dynamic context for elastin fatigue. J Biomech 2009;42:1010-1016.
41. Briones AM, Gonzalez JM, Somoza B, et al. Role of elastin in spontaneously hypertensive rat small mesenteric artery remodelling. J Physiol 2003; 552:185-195.
42. Jimenez-Altayo F, Mart́in A, Rojas S, et al. Transient middle cerebral artery occlusion causes different structural, mechanical, and myogenic alterations in normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 293:H628-H635.
43. Boumaza S, Arribas SM, Osborne-Pellegrin M, et al. Fenestrations of the carotid internal elastic lamina and structural adaptation in stroke-prone spontaneously hypertensive rats. Hypertension 2001; 37:1101-1107.
44. Arribas SM, Briones AM, Bellingham C, et al. Heightened aberrant deposition of hard-wearing elastin in conduit arteries of prehypertensive SHR is associated with increased stiffness and inward remodeling. Am J Physiol Heart Circ Physiol 2008; 295:H2299-H2307.
45. Gonzalez JM, Briones AM, Somoza B, et al. Postnatal alterations in elastic fiber organization precede resistance artery narrowing in SHR. Am J Physiol Heart Circ Physiol 2006; 291:H804-H812.
46. Robert L Cell-elastin interaction and signaling. Pathol Biol (Paris) 2005; 53:399-404.
47. KarnikSK, Brooke BS, Bayes-Genis A, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003; 130:411-423.
48. Faury G, Ristori MT, Verdetti J, et al. Effect of elastin peptides on vascular tone. J Vasc Res 1995; 32:112-119.
49. Fulop T Jr, Douziech N, Jacob MP, et al. Age-related alterations in the signal transduction pathways of the elastin-laminin receptor. Pathol Biol (Paris) 2001; 49:339-348.
50. Mochizuki S, Brassart B, HinekA. Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. J Biol Chem 2002; 277:44854-44863.
51. Brassart B, Fuchs P, Huet E, et al. Conformational dependence of collage-nase (matrix met alloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts. J Biol Chem 2001; 276:5222-5227.
52. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II.CurrOpin Nephrol Hypertens 2005; 14:1 25-131.
53. Spofford CM, Chilian WM. Mechanotransduction via the elastin-laminin receptor (ELR) in resistance arteries. J Biomech 2003; 36:645-652.
54. Klein EA, Yin L, Kothapalli D, et al. Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol 2009; 19:1511-1518.
55. Bezie Y, LamaziereJM, Laurent S, et al. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998; 18:1027-1034.
56. Ruperez M, Lorenzo O, Blanco-Colio LM, et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003; 108:1499-1505. (Pubitemid 37176458)
57. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix met alloproteinases in resistance arteries. Hypertension 2005; 46:598-606.
58. Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell 2002; 13:3546-3559.
59. Chiang HY, Korshunov VA, Serour A, et al. Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler Thromb Vasc Biol 2009; 29:1074-1079.
60. Heerkens EH, Izzard AS, Heagerty AM. Integrins, vascular remodeling, and hypertension. Hypertension 2007; 49:1-4.
61. Martinez-Lemus LA, Sun Z, Trache A, et al. Integrins and regulation of the microcirculation: from arterioles to molecular studies using atomic force microscopy. Microcirculation 2005; 12:99-112.
62. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and spontaneously hypertensive rats: effects of angiotensin receptor antagonism and extracellular components in converting enzyme inhibition. Circulation 1999; 100:2267-2275.
63. Heerkens EH, Shaw L, Ryding A, et al. alphaV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension. Hypertension 2006; 47:281-287.
64. Brassard P, Amiri F, Thibault G, Schiffrin EL. Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Hypertension 2006; 47:122-127.
65. BobikA,TkachukV. Met alloproteinases and plasminogen activators in vessel remodeling. Curr Hypertens Rep 2003; 5:466-472.
66. Raffetto JD, Khalil RA. Matrix met alloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75:346-359.
67. Jacob MP. Extracellular matrix remodeling and matrix met alloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57:195-202.
68. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.
69. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix met alloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17:119-124.
70. Ergul A, Portik-Dobos V, Hutchinson J, et al. Downregulation of vascular matrix met alloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004; 17:775-782.
71. Yasmin SW, McEniery CM, Wallace S, et al. Matrix met alloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:372.
72. Spiers JP, Kelso EJ, Siah WF, et al. Alterations in vascular matrix met alloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens 2005; 23:1717-1724.
73. Watts SW, Rondelli C, Thakali K, et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 292:H2438-H2448.
74. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Met alloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198:320-331.
75. Flamant M, Placier S, Dubroca C, et al. Role of matrix met alloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50:212-218.
76. Hou Y, Okada K, Okamoto C, et al. Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling. Arterioscler Thromb Vasc Biol 2008; 28:1257-1262.
77. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106:2848-2853.
78. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003; 42:49-55.
79. Cachofeiro V, Miana M, de Las Heras N, et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008; 109:331-335.
80. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45:773-779.
81. Ruiz-Ortega M, Rodŕiguez-Vita J, Sanchez-Lopez E, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74:196-206.
82. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol;2007:8:857-869.
83. Belmadani S, Zerfaoui M, Boulares HA, et al. Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 2008; 295:H69-H76.
84. Fu K, Corbley MJ,Sun L, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 2008; 28:665-671.
85. Rodríguez-Vita J, Ruiz-Ortega M, Ruperez M, et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005; 97:125-134.
86. CheZQ, GaoPJ,Shen WL, et al. Angiotensin II-stimulated collagen synthesis in aortic adventitial fibroblasts is mediated by connective tissue growth factor. Hypertens Res 2008; 31:1233-1240.
87. Zacchigna L, Vecchione C, Notte A, et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006; 124:929-942.
88. Nishimura SL Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol 2009; 175:1362-1370.
89. Iglarz M, Touyz RM, Viel EC, et al. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotension system. Am J Hypertens 2004; 17:597-603.
90. Somoza B, Abderrahim F, Gonzalez JM, et al. Short-term treatment of spontaneously hypertensive rats with liver growth factor reduces carotid artery fibrosis, improves vascular function, and lowers blood pressure. Cardiovasc Res 2006; 69:764-771.
91. Condezo-Hoyos L, Abderrahim F, Conde MV, et al. Antioxidant activity of liver growth factor, a bilirubin covalently bound to albumin. Free Radic Biol Med 2009; 46:656-662.
92. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71:247-258.
93. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal 2008; 10:1045-1059.
94. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29:367-374.
95. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46:1118-1122.
96. Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008; 51:1651-1657.
97. Letavernier E, Perez J, Bellocq A, et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008; 102:720-728.
98. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009. [Epub ahead of print]
99. Briones AM, Touyz RM. Moderate exercise decreases inflammation and oxidative stress in hypertension. But what are the mechanisms? Hypertension 2009; 54:1206-1208.
100. ParkJB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 2000; 1:40-45.
101. Rizzoni D, Porteri E, DeCiuceisC, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005; 45:659-665.
102. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101:441-454.
103. Miao CY, Xie HH, Wang JJ, Su DF. Candesartan inhibits sinoaortic denerva-tion-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23:713-720.
104. Neves MF, Virdis A, Schiffrin EL. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 2003; 21:189-198.
105. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51:432-439.
106. de las Heras N, Ruiz-Ortega M, Miana M, et al. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 2007; 25:629-638. (Pubitemid 46213802)
107. Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45:1194-1199.
108. Sharifi AM, Li JS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1 998; 16:457-466.
109. Shirai H, Autieri M, Eguchi S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 2007; 16:111-115.
110. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39:1020-1025.
111. Yasmin, O'Shaughnessy KM. Genetics of arterial structure and function: towards new biomarkers for aortic stiffness. Clin Sci (Lond) 2008; 114:661-677.
112. Boutouyrie P, Laurent S, Briet M. Importance of arterial stiffness as cardiovascular risk factor for future development of new type of drugs. Fundam Clin Pharmacol 2008; 22:241-246.
113. Jarvelainen H, Sainio A, Koulu M, et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61:198-223.